Abstract
When administering antipsychotics, the literature devotes sufficient space to their eggectiveness on positive symptoms. Cardiovascular and metabolic side effects of antipsychotic medication and appropriate recommendations for their correction are often discussed.
Recently, the impact of antipsychotics on negative symptoms has also been amply depicted. The topic of hyperprolactinemia and especially osteoporosis in relation to antipsychotic treatment is less common in the Czech literature.
However, it is likely that by improving the treatment of psychoses, patients will live to an older age, and the more they may face the consequences of drug-induced hyperprolactinemia, including osteoporosis. Antipsycotic treatment often causes an increase pogonadism.
This then directly or indirectly affects bone metabolism. The ability of particular antipsychotics to affect prolactinemia may direct the steps in reduction of the long-term antipsychotic treatment induced osteoporosis risk.